REPORT ID 6273

EMEA (Europe, Middle East and Africa) T Cell Antigen Gp39 Market Report 2017

Publish Date
25-Dec-17
Pages
105
Format
Electronic (PDF)

In this report, the EMEA T Cell Antigen Gp39 market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of T Cell Antigen Gp39 for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA T Cell Antigen Gp39 market competition by top manufacturers/players, with T Cell Antigen Gp39 sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Biogen, Inc.
    Bristol-Myers Squibb Company
    eTheRNA Immunotherapies NV
    ImmuNext, Inc.
    Juno Therapeutics Inc.
    MedImmune, LLC
    Targovax AS
    XL-protein GmbH

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    ECI-006
    Hepatitis B vaccine
    INX-021
    ISF-35
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Graft Versus Host Disease
    Breast Cancer
    Bladder Cancer
    Panceratic Cancer
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) T Cell Antigen Gp39 Market Report 2017
1 T Cell Antigen Gp39 Overview
    1.1 Product Overview and Scope of T Cell Antigen Gp39
    1.2 Classification of T Cell Antigen Gp39
        1.2.1 EMEA T Cell Antigen Gp39 Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA T Cell Antigen Gp39 Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 ECI-006
        1.2.4 Hepatitis B vaccine
        1.2.5 INX-021
        1.2.6 ISF-35
        1.2.7 Others
    1.3 EMEA T Cell Antigen Gp39 Market by Application/End Users
        1.3.1 EMEA T Cell Antigen Gp39 Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Graft Versus Host Disease
        1.3.3 Breast Cancer
        1.3.4 Bladder Cancer
        1.3.5 Panceratic Cancer
        1.3.6 Others
    1.4 EMEA T Cell Antigen Gp39 Market by Region
        1.4.1 EMEA T Cell Antigen Gp39 Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of T Cell Antigen Gp39 (2012-2022)
        1.5.1 EMEA T Cell Antigen Gp39 Sales and Growth Rate (2012-2022)
        1.5.2 EMEA T Cell Antigen Gp39 Revenue and Growth Rate (2012-2022)

2 EMEA T Cell Antigen Gp39 Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA T Cell Antigen Gp39 Market Competition by Players/Manufacturers
        2.1.1 EMEA T Cell Antigen Gp39 Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA T Cell Antigen Gp39 Revenue and Share by Players (2012-2017)
        2.1.3 EMEA T Cell Antigen Gp39 Sale Price by Players (2012-2017)
    2.2 EMEA T Cell Antigen Gp39 (Volume and Value) by Type/Product Category
        2.2.1 EMEA T Cell Antigen Gp39 Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA T Cell Antigen Gp39 Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA T Cell Antigen Gp39 Sale Price by Type (2012-2017)
    2.3 EMEA T Cell Antigen Gp39 (Volume) by Application
    2.4 EMEA T Cell Antigen Gp39 (Volume and Value) by Region
        2.4.1 EMEA T Cell Antigen Gp39 Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA T Cell Antigen Gp39 Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA T Cell Antigen Gp39 Sales Price by Region (2012-2017)

3 Europe T Cell Antigen Gp39 (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe T Cell Antigen Gp39 Sales and Value (2012-2017)
        3.1.1 Europe T Cell Antigen Gp39 Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe T Cell Antigen Gp39 Revenue and Growth Rate (2012-2017)
    3.2 Europe T Cell Antigen Gp39 Sales and Market Share by Type
    3.3 Europe T Cell Antigen Gp39 Sales and Market Share by Application
    3.4 Europe T Cell Antigen Gp39 Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe T Cell Antigen Gp39 Sales Volume by Countries (2012-2017)
        3.4.2 Europe T Cell Antigen Gp39 Revenue by Countries (2012-2017)
        3.4.3 Germany T Cell Antigen Gp39 Sales and Growth Rate (2012-2017)
        3.4.4 France T Cell Antigen Gp39 Sales and Growth Rate (2012-2017)
        3.4.5 UK T Cell Antigen Gp39 Sales and Growth Rate (2012-2017)
        3.4.6 Russia T Cell Antigen Gp39 Sales and Growth Rate (2012-2017)
        3.4.7 Italy T Cell Antigen Gp39 Sales and Growth Rate (2012-2017)
        3.4.8 Benelux T Cell Antigen Gp39 Sales and Growth Rate (2012-2017)

4 Middle East T Cell Antigen Gp39 (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East T Cell Antigen Gp39 Sales and Value (2012-2017)
        4.1.1 Middle East T Cell Antigen Gp39 Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East T Cell Antigen Gp39 Revenue and Growth Rate (2012-2017)
    4.2 Middle East T Cell Antigen Gp39 Sales and Market Share by Type
    4.3 Middle East T Cell Antigen Gp39 Sales and Market Share by Application
    4.4 Middle East T Cell Antigen Gp39 Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East T Cell Antigen Gp39 Sales Volume by Countries (2012-2017)
        4.4.2 Middle East T Cell Antigen Gp39 Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia T Cell Antigen Gp39 Sales and Growth Rate (2012-2017)
        4.4.4 Israel T Cell Antigen Gp39 Sales and Growth Rate (2012-2017)
        4.4.5 UAE T Cell Antigen Gp39 Sales and Growth Rate (2012-2017)
        4.4.6 Iran T Cell Antigen Gp39 Sales and Growth Rate (2012-2017)

5 Africa T Cell Antigen Gp39 (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa T Cell Antigen Gp39 Sales and Value (2012-2017)
        5.1.1 Africa T Cell Antigen Gp39 Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa T Cell Antigen Gp39 Revenue and Growth Rate (2012-2017)
    5.2 Africa T Cell Antigen Gp39 Sales and Market Share by Type
    5.3 Africa T Cell Antigen Gp39 Sales and Market Share by Application
    5.4 Africa T Cell Antigen Gp39 Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa T Cell Antigen Gp39 Sales Volume by Countries (2012-2017)
        5.4.2 Africa T Cell Antigen Gp39 Revenue by Countries (2012-2017)
        5.4.3 South Africa T Cell Antigen Gp39 Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria T Cell Antigen Gp39 Sales and Growth Rate (2012-2017)
        5.4.5 Egypt T Cell Antigen Gp39 Sales and Growth Rate (2012-2017)
        5.4.6 Algeria T Cell Antigen Gp39 Sales and Growth Rate (2012-2017)

6 EMEA T Cell Antigen Gp39 Manufacturers/Players Profiles and Sales Data
    6.1 Biogen, Inc.
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 T Cell Antigen Gp39 Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Biogen, Inc. T Cell Antigen Gp39 Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Bristol-Myers Squibb Company
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 T Cell Antigen Gp39 Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Bristol-Myers Squibb Company T Cell Antigen Gp39 Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 eTheRNA Immunotherapies NV
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 T Cell Antigen Gp39 Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 ImmuNext, Inc.
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 T Cell Antigen Gp39 Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 ImmuNext, Inc. T Cell Antigen Gp39 Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Juno Therapeutics Inc.
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 T Cell Antigen Gp39 Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Juno Therapeutics Inc. T Cell Antigen Gp39 Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 MedImmune, LLC
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 T Cell Antigen Gp39 Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 MedImmune, LLC T Cell Antigen Gp39 Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Targovax AS
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 T Cell Antigen Gp39 Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Targovax AS T Cell Antigen Gp39 Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 XL-protein GmbH
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 T Cell Antigen Gp39 Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 XL-protein GmbH T Cell Antigen Gp39 Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview

7 T Cell Antigen Gp39 Manufacturing Cost Analysis
    7.1 T Cell Antigen Gp39 Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of T Cell Antigen Gp39

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 T Cell Antigen Gp39 Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of T Cell Antigen Gp39 Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA T Cell Antigen Gp39 Market Forecast (2017-2022)
    11.1 EMEA T Cell Antigen Gp39 Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA T Cell Antigen Gp39 Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA T Cell Antigen Gp39 Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA T Cell Antigen Gp39 Price and Trend Forecast (2017-2022)
    11.2 EMEA T Cell Antigen Gp39 Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe T Cell Antigen Gp39 Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt T Cell Antigen Gp39 Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa T Cell Antigen Gp39 Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA T Cell Antigen Gp39 Sales Forecast by Type (2017-2022)
    11.7 EMEA T Cell Antigen Gp39 Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer